Free FIT kits at DMV aim to slash colorectal cancer in african americans
NCT ID NCT05903885
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving free colorectal cancer screening kits (FIT) to African Americans at a DMV office in Omaha can boost screening rates. 1,200 participants aged 45-75 will receive a kit, educational materials, and reminders. Half will also see social media ads. Researchers will compare how many return the kits and follow up on positive results.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Fecal Immunochemical Test (FIT) kit
- What this could lead to
- If successful, this approach could increase colorectal cancer screening rates and reduce deaths in a high-risk community.
- What could go wrong
- This is a behavioral study, not a drug trial. It may not change long-term screening habits, and results may not apply outside Nebraska.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 1,200 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2023
- Expected to finish
-
Oct 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
45 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Self-identification as Black or African American * Between 45 and 75 years old * Not up-to-date with colorectal cancer (CRC) screening per guidelines * Willingness to provide contact information for follow-up * Ability to speak, read, and write English * Current residency in Douglas County, NE. Exclusion Criteria: * History of colorectal cancer (CRC) * History of adenomas (precancerous polyps) or inflammatory bowel disease * Family history of colorectal cancer (CRC)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Colorectal cancer are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The study's own enquiry address
This study publishes an address for enquiries. See it below .
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Motor Vehicles (DMV)
RECRUITINGOmaha, Nebraska, 68104, United States
Contact Email: •••••@•••••
-
Douglas County Treasurer's Office
RECRUITINGOmaha, Nebraska, 68104, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ivosidenib plus mFOLFOXIRI and celecoxib as a treatment for BRAF-targeted therapy-refractory BRAF V600E-mutant colorectal cancer patients: a phase II study
- Can a new drug shrink advanced solid tumors?
- Can a new drug shrink tumors that resist standard care?
- A single blood draw to detect five cancers before symptoms appear?
- Can a new drug duo shrink Hard-to-Treat tumors?
- Could a simple mineral calm the Body's Post-Surgery fire?